CollPlant and Stratasys Announce Pioneering Study for 3D Printed Breast Implants

CollPlant Biotechnologies CLGN and Stratasys Ltd. SSYS, two innovative players in the biomedical and 3D printing industries, respectively, have launched a groundbreaking pre-clinical study. This study concentrates on the development and testing of 200cc regenerative breast implants, which are being fabricated using advanced 3D printing technology from a Stratasys Origin printer. The primary focus of the research is to investigate the implant's potential in fostering the growth of natural breast tissue, signaling a major step forward in regenerative medicine and the use of bioprinting in medical procedures.

Background of Collaborating Companies

ABM Industries Incorporated ABM, with its headquarters in New York, New York, is well-known for providing integrated facility solutions across the United States and internationally. On the other hand, Stratasys Ltd., based in Eden Prairie, Minnesota, is a leader in connected, polymer-based 3D printing solutions. Both companies bring their expertise in their respective fields to the table in this collaborative study, aiming to innovate and potentially revolutionize the medical implants industry.

The Significance of the Study for Future Implats

The success of this study could have a profound impact on not just breast implant surgeries but also the wider field of organ and tissue replacement. By leveraging the precision and customization capabilities of 3D printing, the implants designed by CollPlant and Stratasys have the potential to provide more natural outcomes and better integration with the patient’s body. This could reduce rejection rates and improve the overall effectiveness of implant surgeries.

CollPlant, Stratasys, 3DPrinting